Pay in 4 interest-free payments of $6.53 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
GLP-1 receptor agonists work by mimicking incretin hormones that regulate insulin secretion, appetite signalling, and gastric function as described in clinical pharmacology literature [1]
For example, in the STEP trials with semaglutide, participants lost up to 17% of their body weight over 68 weeks
The primary concern, especially for those taking GLP-1s for weight management, is the very real risk of regaining any weight youve lost while on the medication
We know what works and can guide you toward the best treatments to help you reclaim your energy and improve your quality of life
In our latest post, Jonathan Longden explores the evolving GLP-1 market, key scientific and manufacturing considerations, and the importance of integrated analytical, formulation and regulatory support in accelerating successful drug development programmes
Semaglutide produces average weight loss of 10-15% of body weight
